New study data presented by the Juvenile Diabetes Research Foundation (JDRF) today at the 44th annual meeting of the European Association for the Study of Diabetes (EASD), showed the use of Continuous Glucose Monitoring (CGM) to be effective in the management of Type 1 Diabetes.
The JDRF initiated the study to help increase access to and reimbursement of this new technology, which has been heralded as one of the most significant advancements in diabetes self-management in the past decade. The 322 person, six-month, multi-center randomized trial included both pediatric and adult patients who used either insulin pumps or multiple daily injections to manage their diabetes. The study was conducted in the United States, and utilized all three commercially-available CGM systems, including the Seven® System – developed by San Diego based DexCom™, Inc.
Highlights of the study results include:
- Patients 25 years of age or older who used CGM showed significant improvement in glucose control as measured by HbA1c.
- Most importantly, this improvement in control was observed without an increase in hypoglycemia (low blood sugar), which is a common concern in intensively managed patients trying to achieve improved glucose control.
- In all ages, patients who used CGM at least six days a week had substantially improved HbA1c levels.
“As the only company with an FDA approved seven-day sensor, we believe the Seven System allows patients the unique opportunity to achieve better glucose control. We applaud the JDRF for supporting outcomes studies in the area of CGM technology and are extremely encouraged by their results, which independently validate the effectiveness of this therapy.” said Terrance H. Gregg, DexCom’s President and CEO. “We are particularly excited that the positive results of this study are expected to continue to build momentum with the payer community, leading to greater patient access to the technology.”
"The findings from this study demonstrate continuous glucose monitoring devices, such as DexCom’s Seven System can be safely and effectively used by patients,” said Steve Edelman M.D., Professor of Medicine, University of California, San Diego, and Founder of Taking Control of Your Diabetes, a patient advocacy organization. “As an Endocrinologist and CGM user myself, I believe this technology will rapidly become the standard of care for diabetes management and can truly change the lives of people with diabetes.”
DexCom, Inc.(NASDAQ:DXCM), headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for people with diabetes.
Contacts:
Steven R. Pacelli
Senior Vice President of
Corporate Affairs
858-200-0200
spacelli@dexcom.com
